ELMWOOD PARK, N.J.,
July 9, 2020 /PRNewswire/
-- BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ: OPK), will conduct COVID-19 testing for all Major League
Soccer (MLS) players as well as match officials, and Club and
League staff participating in the MLS is Back Tournament. MLS has
chosen BioReference as its laboratory to assist in informing its
return-to-play policies for the Tournament kicking off in
Orlando in early July.
In addition to providing testing to players, match officials,
and staff, MLS is working with BioReference to provide COVID-19
antibody testing to the Orlando
community. MLS is supporting the latest community collection
location at the Orlando Vineland Premium Outlets, which began on
July 6. The collection location is
open Mondays through Saturdays from 8:00 AM
to 6:00 PM ET.
"We are honored to be providing testing solutions to Major
League Soccer as it prepares to restart its season," said
Jon R. Cohen, M.D., Executive
Chairman of BioReference Laboratories. "The leadership of MLS
worked diligently with us to develop a COVID-19 PCR and antibody
testing strategy with the goal of providing the safest possible
environment for the players, coaches and staff to begin to play
again."
For more information, visit
https://www.bioreference.com/coronavirus/employers-and-government-authorities/.
About BioReference Laboratories, Inc.
BioReference
provides comprehensive testing to physicians, clinics, hospitals,
employers, government units, correctional institutions and medical
groups. BioReference has been working expeditiously to
develop and offer test services that will yield high quality and
accurate results, including a molecular test for helping with
COVID-19 diagnosis and a serology test to help indicate possible
COVID-19 exposure. The company is in network with the five largest
health plans in the United States,
operates a network of 11 laboratory locations, and is backed by a
medical staff of more than 120 M.D.,
Ph.D. and other professional level clinicians and scientists.
With a leading position in the areas of genetics, women's health,
maternal fetal medicine, oncology and urology, BioReference and its
specialty laboratories, GenPath and GeneDx, are advancing the
course of modern medicine. For more information,
visit www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational
biopharmaceutical and diagnostics company that seeks to establish
industry-leading positions in large, rapidly growing markets by
leveraging its discovery, development, and commercialization
expertise and novel and proprietary technologies. For more
information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," as that term is defined under the Private Securities
Litigation Reform Act of 1995 (PSLRA), which statements may be
identified by words such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
BioReference's antibody screening test, the availability of the
test and the role and value of the information provided and its
impact on decisions relative to the safety of employees and
customers, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business,
technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or
results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include
those described in the OPKO Health, Inc. Annual Reports on Form
10-K filed and to be filed with the Securities and Exchange
Commission and in its other filings with the Securities and
Exchange Commission. In addition, forward-looking statements may
also be adversely affected by general market factors, competitive
product development, product availability, federal and state
regulations and legislation, the regulatory process for new
products and indications, manufacturing issues that may arise,
patent positions and litigation, among other factors. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/major-league-soccer-chooses-opko-healths-bioreference-laboratories-to-provide-covid-19-testing-for-players-and-employees-301090547.html
SOURCE BioReference Laboratories, Inc